Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Alnylam Pharmaceuticals Inc shares valued at $547,929 were sold by Garg Pushkal on Jan 12 ’26. At $362.87 per share, Garg Pushkal sold 1,510 shares. The insider’s holdings dropped to 22,511 shares worth approximately $8.23 million following the completion of this transaction.
Also, Greenstreet Yvonne sold 9,577 shares, netting a total of over 3,475,157 in proceeds. Following the sale of shares at $362.86 each, the insider now holds 78,411 shares.
Before that, Poulton Jeffrey V. had sold 2,780 shares from its account. In a trade valued at $1,008,766, the EVP, Chief Financial Officer traded Alnylam Pharmaceuticals Inc shares for $362.87 each. Upon closing the transaction, the insider’s holdings decreased to 2,780 shares, worth approximately $21.0 million.
Analysts at Wolfe Research upgraded the stock from ‘”an Underperform”‘ to ‘”a Peer perform”‘ outlook in a report released in early August. As of August 04, 2025, Oppenheimer has increased its “Perform” rating to a “an Outperform” for ALNY.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] rose 2.79% to $365.46. The stock’s lowest price that day was $351.55, but it reached a high of $366.0 in the same session. During the last five days, there has been a drop of approximately -1.22%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 48.40%.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 1.57 million shares to 5.53 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 3.96 million shares. A jump of 28.42% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.39 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.39.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 493 in the next 12 months, up nearly 38.67% from the previous closing price of $355.53. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 570 by 2026, with the lowest price target being 351. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2026. On July 21, 2025, Truist assigned a price target of “a Buy” to the stock and initiated coverage with a $385.
